Biotechnology analyst, TD Cowen
Appears in 1 story
Last updated Nov 17, 2026
Said the rejection is consistent with the FDA's high bar
Summit Therapeutics' shares fell 15% on Nov. 16. The drop followed the Food and Drug Administration's rejection of ivonescimab, a lung cancer drug that targets two proteins called PD-1 and VEGF and had drawn attention as a potential challenge to Merck's Keytruda. The agency issued a complete response letter, meaning the application cannot be approved in its current form.
Updated 48 minutes ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?